Psoriasis is an autoimmune disease that affects over 125 million people worldwide, that is up to 3% of the total population! At AnTolRx, our targeted approach actively promotes immune tolerance by inducing an anti-inflammatory phenotype and thus better treat disease....
We will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Woods Hole, MA, on October 12-13th, 2019. http://www.newenglandimmunology.org
Dr. Sara Tezza will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Boston March 26-28, 2019. http://as-immunetolerance.com
We are excited to attend this year's 37th annual JP Morgan Healthcare conference in San Francisco, CA this Monday January 7th through the 10th.
World Vaccine Congress Investor Panel, April 4th “…..Mr Carthy commented that “antigen specific tolerance has the potential to deliver disease modifying therapy for indications including autoimmune, allergies and protein drug antibody reactions. AnTolRx has...
Dr. Francisco J Quintana will be presenting data on AnTolRx's antigen-specific nanoparticle platform. Join us in Boston April 24-26, 2018. http://as-immunetolerance.com
We are excited to attend the 36th annual JP Morgan Healthcare Conference in San Francisco, CA from January 8th-11th, 2018.